News
-
-
PRESS RELEASE
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
Transgene expands myvac® into Non-Small Cell Lung Cancer with TG4070, an individualized neoantigen therapeutic vaccine. New randomized Phase 1 trial in NSCLC announced, combining innovative technologies for faster vaccine supply -
-
PRESS RELEASE
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
Transgene to present preclinical data on novel TG-MVA prophylactic vaccine against mpox at World Congress on Infectious Diseases. Focus on Orthopoxvirus-related diseases. Oral presentation by Head of Vectorology Laboratory, Nathalie Silvestre -
-
-
-
-
PRESS RELEASE
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene completes patient randomization in Phase 2 of clinical trial for TG4050 in adjuvant treatment of head and neck cancer. Top-line results expected by Q1 2028 -
